The myAirvo therapy system – humidified high flow for home use

Ease symptoms.
Reduce escalation of care.
Improve quality of life.

Product enquiry

Frequent coughs, breathlessness and hospitalization can seriously impact the wellbeing of patients with respiratory conditions such as chronic obstructive pulmonary disease (COPD). The myAirvo™ system delivers humidified high flow therapy to chronic respiratory patients at home and in long-term care facilities.

Humidified high flow therapy delivers a mix of warm, moist air and supplementary oxygen (when required) to help COPD patients:

Ease respiratory disease symptoms^1,2,5

Reduce escalation of care^1,3,5

Improve quality of life^1-5

Mechanisms of action explained

The search is on to find better treatments for chronic obstructive pulmonary disease (COPD) patients.

More than 15.7 million Americans report being diagnosed with COPD, so we’re delighted to be supporting a clinical trial, HiFlo COPD, evaluating the effect of nasal high flow therapy in COPD patients in the home.

The multi-center trial is being led by Temple University Hospital in Philadelphia.

Find out more

myAirvo 2

Deliver Optimal Humidity using advanced respiratory technology with myAirvo 2.

View myAirvo 2

Optiflow™ interfaces

Ensure comfort and fit with a range of nasal cannulas, tracheostomy and mask adapter interfaces, including pediatric sizes.

View Optiflow interfaces

For the delivery of humidified high flow therapy in hospitals

Airvo 2™ delivers nasal high flow therapy to a broad range of patients in all areas of the hospital.

Learn more about Airvo 2

Storgaard LH, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 2018;13:1195-1205. View abstract
Storgaard LH, et al. COPD Patients’ Experience of Long-Term Domestic Oxygen-Enriched Nasal High Flow Treatment: A Qualitative Study. COPD. 2020;17(2). View abstract
Rea H, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med 2010;104:525-533. View abstract
Nagata K, et al. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc 2018;15:432–9. doi:10.1513/AnnalsATS.201706-425OC. View abstract
Nagata K, et al. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD Patients: A Randomized Trial. American Journal of Respiratory and Critical Care Medicine. 2022, 206 (11). View abstract

View references

F&P, myAirvo, Airvo and Optiflow are trademarks of Fisher & Paykel Healthcare Limited. For patent information, see www.fphcare.com/ip